When brain sections of cases that demonstrated specific binding (i.e., AD and PiD cases) were incubated with a mixture of high molar activity [18F]AV1451 and a high concentration of the MAO-B inhibitor deprenyl, no reduction in tracer binding was observed in the current study. This evidence concerns the gene MAOB and Alzheimer disease.